Charles Schwab’s Terns Pharmaceuticals TERN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-747,377
| Closed | -$39.4M | – | 3552 |
|
|
2026
Q1 | $39.4M | Buy |
747,377
+10,217
| +1% | +$420K | 0.01% | 1306 |
|
|
2025
Q4 | $29.8M | Buy |
737,160
+153,892
| +26% | +$3.56M | ﹤0.01% | 1496 |
|
|
2025
Q3 | $4.38M | Buy |
583,268
+359,048
| +160% | +$2.29M | ﹤0.01% | 2497 |
|
|
2025
Q2 | $836K | Buy |
224,220
+17,770
| +9% | +$55.5K | ﹤0.01% | 2955 |
|
|
2025
Q1 | $570K | Hold |
206,450
| – | – | ﹤0.01% | 3034 |
|
|
2024
Q4 | $1.14M | Buy |
206,450
+51,736
| +33% | +$350K | ﹤0.01% | 2867 |
|
|
2024
Q3 | $1.29M | Buy |
154,714
+1,994
| +1% | +$16.4K | ﹤0.01% | 2839 |
|
|
2024
Q2 | $1.04M | Buy |
152,720
+38,111
| +33% | +$231K | ﹤0.01% | 2919 |
|
|
2024
Q1 | $752K | Hold |
114,609
| – | – | ﹤0.01% | 2882 |
|
|
2023
Q4 | $744K | Hold |
114,609
| – | – | ﹤0.01% | 2929 |
|
|
2023
Q3 | $576K | Hold |
114,609
| – | – | ﹤0.01% | 2993 |
|
|
2023
Q2 | $1M | Buy |
114,609
+100,898
| +736% | +$1.18M | ﹤0.01% | 2764 |
|
|
2023
Q1 | $162K | Buy |
+13,711
| New | +$131K | ﹤0.01% | 3191 |
|
|
2022
Q4 | – | Sell |
-12,408
| Closed | -$74K | – | 3564 |
|
|
2022
Q3 | $74K | Buy |
+12,408
| New | +$46.1K | ﹤0.01% | 3250 |
|
|
2022
Q2 | – | Sell |
-28,746
| Closed | -$86K | – | 3639 |
|
|
2022
Q1 | $86K | Hold |
28,746
| – | – | ﹤0.01% | 3440 |
|
|
2021
Q4 | $204K | Sell |
28,746
-2,797
| -9% | -$23.3K | ﹤0.01% | 3357 |
|
|
2021
Q3 | $329K | Buy |
31,543
+10,184
| +48% | +$106K | ﹤0.01% | 3245 |
|
|
2021
Q2 | $262K | Hold |
21,359
| – | – | ﹤0.01% | 3254 |
|
|
2021
Q1 | $470K | Buy |
+21,359
| New | +$468K | ﹤0.01% | 3102 |
|
Other funds holding TERN
Charles Schwab's TERN Position: Q2 2026 in Review
Charles Schwab sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 747,377 shares — an estimated $39.4M sold.
Charles Schwab first reported a position in TERN in Q1 2021 and held it in 19 quarters. The position peaked at $39.4M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.
- Charles Schwab reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Charles Schwab sold 747,377 Terns Pharmaceuticals shares in Q2 2026, an estimated $39.4M.
- Charles Schwab first reported a position in Terns Pharmaceuticals in Q1 2021 and held it in 19 quarters.
- Charles Schwab's Terns Pharmaceuticals position peaked at $39.4M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.